Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 1
2010 4
2011 2
2012 2
2013 3
2014 6
2015 4
2016 3
2017 1
2019 5
2020 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Neoantigen Targetability in Progressive Advanced Melanoma.
van den Bulk J, Verdegaal EME, van der Ploeg M, Visser M, Nunes JB, de Ru AH, Tjokrodirijo RTN, Ijsselsteijn ME, Janssen NI, van der Breggen R, de Bruin L, de Kok P, Janssen GMC, Ruano D, Kapiteijn EHW, van Veelen PA, de Miranda NFCC, van der Burg SH. van den Bulk J, et al. Among authors: van der breggen r. Clin Cancer Res. 2023 Oct 13;29(20):4278-4288. doi: 10.1158/1078-0432.CCR-23-1106. Clin Cancer Res. 2023. PMID: 37540567 Free PMC article.
Multimodal profiling of chordoma immunity reveals distinct immune contextures.
van Oost S, Meijer DM, Ijsselsteijn ME, Roelands JP, van den Akker BEMW, van der Breggen R, Briaire-de Bruijn IH, van der Ploeg M, Wijers-Koster PM, Polak SB, Peul WC, van der Wal RJP, de Miranda NFCC, Bovee JVMG. van Oost S, et al. Among authors: van der breggen r. J Immunother Cancer. 2024 Jan 25;12(1):e008138. doi: 10.1136/jitc-2023-008138. J Immunother Cancer. 2024. PMID: 38272563 Free PMC article.
CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden.
van den Bulk J, van der Ploeg M, Ijsselsteijn ME, Ruano D, van der Breggen R, Duhen R, Peeters KCMJ, Fariña-Sarasqueta A, Verdegaal EME, van der Burg SH, Duhen T, de Miranda NFCC. van den Bulk J, et al. Among authors: van der breggen r. J Immunother Cancer. 2023 Feb;11(2):e005887. doi: 10.1136/jitc-2022-005887. J Immunother Cancer. 2023. PMID: 36792124 Free PMC article.
Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study.
Lau SP, Klaase L, Vink M, Dumas J, Bezemer K, van Krimpen A, van der Breggen R, Wismans LV, Doukas M, de Koning W, Stubbs AP, Mustafa DAM, Vroman H, Stadhouders R, Nunes JB, Stingl C, de Miranda NFCC, Luider TM, van der Burg SH, Aerts JG, van Eijck CHJ. Lau SP, et al. Among authors: van der breggen r. Eur J Cancer. 2022 Jul;169:20-31. doi: 10.1016/j.ejca.2022.03.015. Epub 2022 Apr 28. Eur J Cancer. 2022. PMID: 35490565 Free article. Clinical Trial.
Revisiting immune escape in colorectal cancer in the era of immunotherapy.
Ijsselsteijn ME, Petitprez F, Lacroix L, Ruano D, van der Breggen R, Julie C, Morreau H, Sautès-Fridman C, Fridman WH, de Miranda NFDCC. Ijsselsteijn ME, et al. Among authors: van der breggen r. Br J Cancer. 2019 Apr;120(8):815-818. doi: 10.1038/s41416-019-0421-x. Epub 2019 Mar 13. Br J Cancer. 2019. PMID: 30862951 Free PMC article.
Underlying molecular mechanisms of DIO2 susceptibility in symptomatic osteoarthritis.
Bomer N, den Hollander W, Ramos YF, Bos SD, van der Breggen R, Lakenberg N, Pepers BA, van Eeden AE, Darvishan A, Tobi EW, Duijnisveld BJ, van den Akker EB, Heijmans BT, van Roon-Mom WM, Verbeek FJ, van Osch GJ, Nelissen RG, Slagboom PE, Meulenbelt I. Bomer N, et al. Among authors: van der breggen r. Ann Rheum Dis. 2015 Aug;74(8):1571-9. doi: 10.1136/annrheumdis-2013-204739. Epub 2014 Apr 2. Ann Rheum Dis. 2015. PMID: 24695009 Free PMC article.
Aberrant Calreticulin Expression in Articular Cartilage of Dio2 Deficient Mice.
Bomer N, Cornelis FM, Ramos YF, den Hollander W, Lakenberg N, van der Breggen R, Storms L, Slagboom PE, Lories RJ, Meulenbelt I. Bomer N, et al. Among authors: van der breggen r. PLoS One. 2016 May 10;11(5):e0154999. doi: 10.1371/journal.pone.0154999. eCollection 2016. PLoS One. 2016. PMID: 27163789 Free PMC article.
Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
van den Bulk J, Verdegaal EME, Ruano D, Ijsselsteijn ME, Visser M, van der Breggen R, Duhen T, van der Ploeg M, de Vries NL, Oosting J, Peeters KCMJ, Weinberg AD, Farina-Sarasqueta A, van der Burg SH, de Miranda NFCC. van den Bulk J, et al. Among authors: van der breggen r. Genome Med. 2019 Dec 30;11(1):87. doi: 10.1186/s13073-019-0697-8. Genome Med. 2019. PMID: 31888734 Free PMC article.
Disease variants alter transcription factor levels and methylation of their binding sites.
Bonder MJ, Luijk R, Zhernakova DV, Moed M, Deelen P, Vermaat M, van Iterson M, van Dijk F, van Galen M, Bot J, Slieker RC, Jhamai PM, Verbiest M, Suchiman HE, Verkerk M, van der Breggen R, van Rooij J, Lakenberg N, Arindrarto W, Kielbasa SM, Jonkers I, van 't Hof P, Nooren I, Beekman M, Deelen J, van Heemst D, Zhernakova A, Tigchelaar EF, Swertz MA, Hofman A, Uitterlinden AG, Pool R, van Dongen J, Hottenga JJ, Stehouwer CD, van der Kallen CJ, Schalkwijk CG, van den Berg LH, van Zwet EW, Mei H, Li Y, Lemire M, Hudson TJ; BIOS Consortium; Slagboom PE, Wijmenga C, Veldink JH, van Greevenbroek MM, van Duijn CM, Boomsma DI, Isaacs A, Jansen R, van Meurs JB, 't Hoen PA, Franke L, Heijmans BT. Bonder MJ, et al. Among authors: van der breggen r. Nat Genet. 2017 Jan;49(1):131-138. doi: 10.1038/ng.3721. Epub 2016 Dec 5. Nat Genet. 2017. PMID: 27918535
31 results